生物制剂在儿童中重度特应性皮炎治疗中的研究进展

Research progress in the use of biological agents in the treatment of moderate-to-severe pediatric atopic dermatitis

特应性皮炎(atopic dermatitis,AD)是一种慢性、复发性、瘙痒性、炎症性皮肤病,严重影响患者的生存质量。传统治疗如外用糖皮质激素、钙调磷酸酶抑制剂等在中重度患者的治疗中具有局限性。随着对疾病发病机制的深入理解,生物制剂展示出巨大的应用前景。该文总结了有关生物制剂治疗儿童AD患者的临床研究,为临床医生提供相关前沿信息。

Atopic dermatitis(AD)is a chronic,relapsing,pruritic,and inflammatory skin disease that significantly affects patients'quality of life.Traditional treatment options,such as topical corticosteroids and topical calcineurin inhibitors,have limitations in the treatment of moderate-tosevere AD.With an improved understanding of the pathogenesis of AD,biological agents have emerged as a promising treatment option.This article aims to provide clinicians with current and relevant information on the use of biological agents in the treatment of pediatric AD by summarizing the clinlcal trials.